Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns

Results from the BabySeq Project

The BabySeq Project Team

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Genomic sequencing provides many opportunities in newborn clinical care, but the challenges of interpreting and reporting newborn genomic sequencing (nGS) results need to be addressed for its broader and effective application. The BabySeq Project is a pilot randomized clinical trial that explores the medical, behavioral, and economic impacts of nGS in well newborns and those admitted to a neonatal intensive care unit (NICU). Here we present childhood-onset and actionable adult-onset disease risk, carrier status, and pharmacogenomics findings from nGS of 159 newborns in the BabySeq Project. nGS revealed a risk of childhood-onset disease in 15/159 (9.4%) newborns; none of the disease risks were anticipated based on the infants’ known clinical or family histories. nGS also revealed actionable adult-onset disease risk in 3/85 (3.5%) newborns whose parents consented to receive this information. Carrier status for recessive diseases and pharmacogenomics variants were reported in 88% and 5% of newborns, respectively. Additional indication-based analyses were performed in 29/32 (91%) NICU newborns and 6/127 (5%) healthy newborns who later had presentations that prompted a diagnostic analysis. No variants that sufficiently explained the reason for the indications were identified; however, suspicious but uncertain results were reported in five newborns. Testing parental samples contributed to the interpretation and reporting of results in 13/159 (8%) newborns. Our results suggest that nGS can effectively detect risk and carrier status for a wide range of disorders that are not detectable by current newborn screening assays or predicted based on the infant's known clinical or family history, and the interpretation of results can substantially benefit from parental testing.

Original languageEnglish (US)
Pages (from-to)76-93
Number of pages18
JournalAmerican Journal of Human Genetics
Volume104
Issue number1
DOIs
StatePublished - Jan 3 2019

Fingerprint

Newborn Infant
Neonatal Intensive Care Units
Behavioral Economics
Medical Economics
Pharmacogenetics
Randomized Controlled Trials
Parents

Keywords

  • genomic sequencing
  • newborn
  • newborn screening
  • newborn sequencing
  • whole-exome sequencing

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns : Results from the BabySeq Project. / The BabySeq Project Team.

In: American Journal of Human Genetics, Vol. 104, No. 1, 03.01.2019, p. 76-93.

Research output: Contribution to journalArticle

@article{d9d72a4e14384fb98be082a099b724ea,
title = "Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project",
abstract = "Genomic sequencing provides many opportunities in newborn clinical care, but the challenges of interpreting and reporting newborn genomic sequencing (nGS) results need to be addressed for its broader and effective application. The BabySeq Project is a pilot randomized clinical trial that explores the medical, behavioral, and economic impacts of nGS in well newborns and those admitted to a neonatal intensive care unit (NICU). Here we present childhood-onset and actionable adult-onset disease risk, carrier status, and pharmacogenomics findings from nGS of 159 newborns in the BabySeq Project. nGS revealed a risk of childhood-onset disease in 15/159 (9.4{\%}) newborns; none of the disease risks were anticipated based on the infants’ known clinical or family histories. nGS also revealed actionable adult-onset disease risk in 3/85 (3.5{\%}) newborns whose parents consented to receive this information. Carrier status for recessive diseases and pharmacogenomics variants were reported in 88{\%} and 5{\%} of newborns, respectively. Additional indication-based analyses were performed in 29/32 (91{\%}) NICU newborns and 6/127 (5{\%}) healthy newborns who later had presentations that prompted a diagnostic analysis. No variants that sufficiently explained the reason for the indications were identified; however, suspicious but uncertain results were reported in five newborns. Testing parental samples contributed to the interpretation and reporting of results in 13/159 (8{\%}) newborns. Our results suggest that nGS can effectively detect risk and carrier status for a wide range of disorders that are not detectable by current newborn screening assays or predicted based on the infant's known clinical or family history, and the interpretation of results can substantially benefit from parental testing.",
keywords = "genomic sequencing, newborn, newborn screening, newborn sequencing, whole-exome sequencing",
author = "{The BabySeq Project Team} and Ozge Ceyhan-Birsoy and Ozge Ceyhan-Birsoy and Murry, {Jaclyn B.} and Kalotina Machini and Lebo, {Matthew S.} and Rehm, {Heidi L.} and Lebo, {Matthew S.} and Rehm, {Heidi L.} and Murry, {Jaclyn B.} and Kalotina Machini and Lebo, {Matthew S.} and Yu, {Timothy W.} and Agrawal, {Pankaj B.} and Parad, {Richard B.} and Holm, {Ingrid A.} and Green, {Robert C.} and Rehm, {Heidi L.} and Beggs, {Alan H.} and Yu, {Timothy W.} and Genetti, {Casie A.} and Schwartz, {Talia S.} and Agrawal, {Pankaj B.} and Holm, {Ingrid A.} and Beggs, {Alan H.} and Yu, {Timothy W.} and Shawn Fayer and Green, {Robert C.} and Agrawal, {Pankaj B.} and Parad, {Richard B.} and McGuire, {Amy L.} and Lebo, {Matthew S.} and Green, {Robert C.} and Rehm, {Heidi L.} and Rehm, {Heidi L.} and Agrawal, {Pankaj B.} and Beggs, {Alan H.} and Betting, {Wendi N.} and Ozge Ceyhan-Birsoy and Christensen, {Kurt D.} and Dmitry Dukhovny and Shawn Fayer and Frankel, {Leslie A.} and Genetti, {Casie A.} and Chet Graham and Green, {Robert C.} and Guiterrez, {Amanda M.} and Maegan Harden and Holm, {Ingrid A.} and Krier, {Joel B.} and Lebo, {Matthew S.}",
year = "2019",
month = "1",
day = "3",
doi = "10.1016/j.ajhg.2018.11.016",
language = "English (US)",
volume = "104",
pages = "76--93",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns

T2 - Results from the BabySeq Project

AU - The BabySeq Project Team

AU - Ceyhan-Birsoy, Ozge

AU - Ceyhan-Birsoy, Ozge

AU - Murry, Jaclyn B.

AU - Machini, Kalotina

AU - Lebo, Matthew S.

AU - Rehm, Heidi L.

AU - Lebo, Matthew S.

AU - Rehm, Heidi L.

AU - Murry, Jaclyn B.

AU - Machini, Kalotina

AU - Lebo, Matthew S.

AU - Yu, Timothy W.

AU - Agrawal, Pankaj B.

AU - Parad, Richard B.

AU - Holm, Ingrid A.

AU - Green, Robert C.

AU - Rehm, Heidi L.

AU - Beggs, Alan H.

AU - Yu, Timothy W.

AU - Genetti, Casie A.

AU - Schwartz, Talia S.

AU - Agrawal, Pankaj B.

AU - Holm, Ingrid A.

AU - Beggs, Alan H.

AU - Yu, Timothy W.

AU - Fayer, Shawn

AU - Green, Robert C.

AU - Agrawal, Pankaj B.

AU - Parad, Richard B.

AU - McGuire, Amy L.

AU - Lebo, Matthew S.

AU - Green, Robert C.

AU - Rehm, Heidi L.

AU - Rehm, Heidi L.

AU - Agrawal, Pankaj B.

AU - Beggs, Alan H.

AU - Betting, Wendi N.

AU - Ceyhan-Birsoy, Ozge

AU - Christensen, Kurt D.

AU - Dukhovny, Dmitry

AU - Fayer, Shawn

AU - Frankel, Leslie A.

AU - Genetti, Casie A.

AU - Graham, Chet

AU - Green, Robert C.

AU - Guiterrez, Amanda M.

AU - Harden, Maegan

AU - Holm, Ingrid A.

AU - Krier, Joel B.

AU - Lebo, Matthew S.

PY - 2019/1/3

Y1 - 2019/1/3

N2 - Genomic sequencing provides many opportunities in newborn clinical care, but the challenges of interpreting and reporting newborn genomic sequencing (nGS) results need to be addressed for its broader and effective application. The BabySeq Project is a pilot randomized clinical trial that explores the medical, behavioral, and economic impacts of nGS in well newborns and those admitted to a neonatal intensive care unit (NICU). Here we present childhood-onset and actionable adult-onset disease risk, carrier status, and pharmacogenomics findings from nGS of 159 newborns in the BabySeq Project. nGS revealed a risk of childhood-onset disease in 15/159 (9.4%) newborns; none of the disease risks were anticipated based on the infants’ known clinical or family histories. nGS also revealed actionable adult-onset disease risk in 3/85 (3.5%) newborns whose parents consented to receive this information. Carrier status for recessive diseases and pharmacogenomics variants were reported in 88% and 5% of newborns, respectively. Additional indication-based analyses were performed in 29/32 (91%) NICU newborns and 6/127 (5%) healthy newborns who later had presentations that prompted a diagnostic analysis. No variants that sufficiently explained the reason for the indications were identified; however, suspicious but uncertain results were reported in five newborns. Testing parental samples contributed to the interpretation and reporting of results in 13/159 (8%) newborns. Our results suggest that nGS can effectively detect risk and carrier status for a wide range of disorders that are not detectable by current newborn screening assays or predicted based on the infant's known clinical or family history, and the interpretation of results can substantially benefit from parental testing.

AB - Genomic sequencing provides many opportunities in newborn clinical care, but the challenges of interpreting and reporting newborn genomic sequencing (nGS) results need to be addressed for its broader and effective application. The BabySeq Project is a pilot randomized clinical trial that explores the medical, behavioral, and economic impacts of nGS in well newborns and those admitted to a neonatal intensive care unit (NICU). Here we present childhood-onset and actionable adult-onset disease risk, carrier status, and pharmacogenomics findings from nGS of 159 newborns in the BabySeq Project. nGS revealed a risk of childhood-onset disease in 15/159 (9.4%) newborns; none of the disease risks were anticipated based on the infants’ known clinical or family histories. nGS also revealed actionable adult-onset disease risk in 3/85 (3.5%) newborns whose parents consented to receive this information. Carrier status for recessive diseases and pharmacogenomics variants were reported in 88% and 5% of newborns, respectively. Additional indication-based analyses were performed in 29/32 (91%) NICU newborns and 6/127 (5%) healthy newborns who later had presentations that prompted a diagnostic analysis. No variants that sufficiently explained the reason for the indications were identified; however, suspicious but uncertain results were reported in five newborns. Testing parental samples contributed to the interpretation and reporting of results in 13/159 (8%) newborns. Our results suggest that nGS can effectively detect risk and carrier status for a wide range of disorders that are not detectable by current newborn screening assays or predicted based on the infant's known clinical or family history, and the interpretation of results can substantially benefit from parental testing.

KW - genomic sequencing

KW - newborn

KW - newborn screening

KW - newborn sequencing

KW - whole-exome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85058778031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058778031&partnerID=8YFLogxK

U2 - 10.1016/j.ajhg.2018.11.016

DO - 10.1016/j.ajhg.2018.11.016

M3 - Article

VL - 104

SP - 76

EP - 93

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 1

ER -